{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:32:09Z","timestamp":1793406729570,"version":"4.5.0"},"reference-count":37,"publisher":"Baishideng Publishing Group Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Hepatol"],"abstract":"<jats:p>Chronic hepatitis B constitutes a substantial disease burden worldwide. The steps advocated by the World Health Organization in 2016 to eradicate hepatitis B by 2030 has failed to achieve significant progress, especially with respect to immunization coverage and linkage to care. The lack of governmental and public awareness regarding the long-term implications of hepatitis B burden cause underfunding of developmental projects. The presently approved treatment modalities have limited efficacy in complete viral eradication, hence the need for newer molecules to achieve functional cure (sustained undetectable hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA in peripheral blood after a finite period of therapy). However, preliminary results from trials of novel therapies show their inadequacy to achieve this end by themselves but better performance with a low baseline serum HBsAg with nucleos(t)ide analogues (NA) treatment which need to be combined with\/without pegylated interferon as an immunomodulator. Such therapy is limited by cost and adverse events and need to show incremental benefit over the standard of care (long-term NA therapy) with respect to efficacy and drug toxicities, making the development process tenuous. Thus, while such therapies continue to be tested, strategies should still focus on prevention of transmission by non-pharmaceutical measures, vaccination and increasing linkage to care.<\/jats:p>","DOI":"10.4254\/wjh.v16.i9.1199","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T01:38:57Z","timestamp":1727055537000},"page":"1199-1205","source":"Crossref","is-referenced-by-count":7,"title":["Functional cure of chronic hepatitis B-hope or hype?"],"prefix":"10.4254","volume":"16","author":[{"given":"Gautam","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00197-8"},{"key":"B3","unstructured":"World Health Organization.   Hepatitis B. April 9, 2024 [cited 7 May 2024]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31782"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00818-9"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.014"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i23.3279"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.03.002"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.011"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.10.092"},{"key":"B11","unstructured":"World Health Organization.   Immunization coverage. July 18, 2023. [cited 7 May 2024]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage"},{"key":"B12","unstructured":"World Health Organization.   Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards ending viral hepatitis. May 17, 2016. [cited 7 May 2024]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyi206"},{"key":"B14","unstructured":"World Health Organization.   Global Hepatitis Report, 2017. April 19, 2017. [cited 7 May 2024]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241565455"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00321-7"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/v13091767"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"B18","unstructured":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. [cited 27 April 2024]. Available from: https:\/\/www.healthdata.org\/research-analysis\/library\/global-regional-and-national-burden-hepatitis-b-1990-2019-systematic"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.09.013"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00156-5"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0093"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.057"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5009\/gnl240023"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01843-2"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-024-00652-9"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(22)00537-2"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.010"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(24)00471-9"},{"key":"B30","unstructured":"Kennedy PT, Fung SK, Buti M, Gurdal Y, Chuang WL, Asselah T, Kurosaki M, Jejorwski J, Verbinnen T, Kakuda TN, Lenz O, Guinard-Azadian C, Biermer Ml.   Efficacy and safety of siRNA JNJ-73763989, capsid assembly modulator-E (CAME) JNJ-56136379, and nucleos(t)ide analogs (NA) with pegylated interferon alpha-2a (PEGIFN- \u03b12a) added in immune-tolerant patients with chronic hepatitis B virus (HBV) infection: interim results from the phase 2 REEF-IT study. Available from https:\/\/www.natap.org\/2023\/AASLD\/AASLD_30.htm"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1777639"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210027"},{"key":"B33","unstructured":"Gao Z, Yan L, Li J, Hu R, Hu P, Yue W, Lv F, Liu Y, Li C, Liu W, Chen X, Zhu Q.   Phase 2 interim results: BRII-179 (VBI-2601), a protein-based HBV therapeutic vaccine, induced robust HBsAb responses that are strongly associated with increased HBsAg loss in subjects receiving Peg-IFN\u03b1 treatment. Available from: https:\/\/www.briibio.com\/media\/pjzdkb2t\/1-aasld-poster-brii-179-002.pdf"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.08.008"},{"key":"B35","unstructured":"World Health Organization.   Global hepatitis report 2024: action for access in low- and middle-income countries. April 9, 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240091672"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16828"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/v15122395"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v16\/i9\/1199.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v16\/i9\/1199.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T01:39:04Z","timestamp":1727055544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v16\/i9\/1199.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":37,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.4254\/wjh.v16.i9.1199","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}